Ocugen Announces Positive 12-Month Data from Phase 2 ArMaDa Trial for OCU410 Gene Therapy in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration.

Ocugen's Phase 2 trial for OCU410, a gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration, reported a 31% reduction in lesion growth in the optimal dose group compared to control (p< 0.05). This is a potential 2X treatment benefit compared to current therapies. The trial also showed a clean safety profile with no serious adverse events or adverse events of special interest related to OCU410.